These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37369955)

  • 1. Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis.
    Stark JG; Noonan PK; Spencer RH; Bhaduri S; O'Connor SJ; Menzaghi F
    Clin Pharmacokinet; 2023 Sep; 62(9):1231-1241. PubMed ID: 37369955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus.
    Spencer RH; Noonan PK; Marbury T; Menzaghi F
    BMC Nephrol; 2024 Oct; 25(1):351. PubMed ID: 39402448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
    Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
    J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
    Fugal J; Serpa SM
    Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
    Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
    JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
    Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
    Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
    Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
    Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis.
    Spencer RH; Munera C; Shram MJ; Menzaghi F
    Clin Transl Sci; 2023 Sep; 16(9):1559-1568. PubMed ID: 37128642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
    Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
    Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
    Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
    N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function.
    Bradu A; Penescu M; Pitrou C; Hao J; Bourrinet P
    Invest Radiol; 2021 Aug; 56(8):486-493. PubMed ID: 34197356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
    Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F;
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease.
    Hoover R; Alcorn H; Lawrence L; Paulson SK; Quintas M; Cammarata SK
    J Clin Pharmacol; 2018 Jul; 58(7):913-919. PubMed ID: 29537614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
    O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.